New Insights into the Precise Function of CAR T Cells

​ Chimeric antigen receptor (CAR) T-cell therapy modifies the patient's own T cells, otherwise known as natural killer cells or cytotoxic T lymphocytes, to enable the T cells to recognize and eliminate a target molecule, CD19, on the cancerous cells. While this form of immunotherapy has great potential in treating B-cell malignancies, relapse does occur in some patients. Researchers have gained new insights into the outcome and dynamics of CAR T-cell interactions in different anatomical sites, r...
Continue reading

B-Cell Malignancies: Treatment Advances in CAR T-Cell Therapy With Stephanie Jackson, MSN, RN, AOCNS®, BMTCN®

Outcomes have improved in recent years for patients with B-cell malignancies such as diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia (ALL), but many patients continue to develop relapsed or refractory disease. In this interview with i3 Health, Stephanie Jackson, MSN, RN, AOCNS®, BMTCN®, Oncology Clinical Nurse Specialist at the Ronald Reagan UCLA Medical Center, discusses advances in chimeric antigen receptor (CAR) T-cell therapy, which has been shown to produce significant...
Continue reading

First-Line Atezolizumab Approved: Extensive-Stage SCLC

​ The FDA has approved atezolizumab (Tecentriq®, Genentech, Inc.) in combination with carboplatin and etoposide as first-line treatment for patients with extensive-stage (ES) small cell lung cancer (SCLC). This is the first immunotherapy-based combination to be approved in the initial treatment of ES-SCLC. Extensive-stage SCLC has spread widely throughout the lung, to the other lung, to lymph nodes on the other side of the chest, to the fluid around the lung, or to other areas in the body, such ...
Continue reading

Immunotherapy in Triple-Negative Breast Cancer: An Interview With Leisha Emens, MD, PhD

​ The FDA's approval of atezolizumab (Tecentriq®, Genentech, Inc.) in combination with nab-paclitaxel for patients with previously untreated unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) expressing programmed death-ligand 1 (PD-L1) represents the first approval of an immune checkpoint inhibitor for breast cancer. In addition, it is an important development for patients with TNBC, which lacks many of the targeted therapies that can be used in other types of brea...
Continue reading

Antibody-Drug Conjugate Is Powerful Against Neuroblastoma

Researchers at the Cancer Center of Children's Hospital of Philadelphia (CHOP) have developed an antibody-drug conjugate (ADC) that is powerfully effective against mouse models of neuroblastoma expressing wild-type and mutant anaplastic lymphoma kinase (ALK). Neuroblastoma, a cancer of the peripheral nervous system typically found in children younger than 5, is the third most common pediatric cancer and the most common cancer in infants. It accounts for over 10% of all childhood cancer-related d...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.